Bryan Tayefeh is the Senior Manager of Alliance Management at Isis Pharmaceuticals. Recently joining the Corporate Partnering and Alliance Management division at Isis Pharmaceuticals, Bryan brings a unique background of both bench work and business development. He has extensive experience in Bioanalysis where at Isis Pharmaceuticals he spent several years developing and transferring quantitative assays for Antisense Oligonucleotides and led the Immunogenicity research efforts.

Mr. Haodi Dong is Technical Director at WuXi Biologics, responsible for business development on North America east coast and in Europe for the company’s biologics discovery, development and manufacturing services. He earned his B.S. and M.S. in Biochemical Engineering from East China University of Science and Technology, M.S. in Chemical Engineering from Auburn University, and MBA in Health Sector and Operations Management from Boston University. Mr. Dong has over 10 years of experience in the US biopharmaceutical industry and accomplishments in biologics process development, tech transfer and GMP manufacturing support (monoclonal antibodies, enzyme replacement therapies, gene therapy, and cell banking). Prior to joining WuXi, he served as Project Lead in Upstream Operations for the large scale biologics commercial manufacturing at Bristol-Myers Squibb in Devens MA, up to Senior Process Engineer (Manager) in Biologics Late Stage Process Development at Genzyme, a Sanofi company in Framingham MA, and BioProcess Engineer II at CuraGen in Branford CT. He is particularly proficient and experienced in bioprocess technology and processes, especially upstream such as fed-batch, perfusion, and cell banking.

Ryan Iarrobino is Senior Director, Clinical Development at Dyax Corp. Since joining Dyax in 2008, Ryan has had the great fortune to be involved in a BLA approval, several IND submissions, FDA and EMA interactions, as well as carry out numerous early and late-phase clinical trials, including a First in Human study with a novel biologic in an orphan disease. Prior to Dyax, Ryan worked for CROs where he focused on clinical data capture and analysis across a multitude of different therapeutic areas. When Ryan is not recruiting patients to participate in clinical trials or crunching numbers he spends his time enjoying as many outdoor activities as he can.

Dr. Lorraine Rusch is an executive level business development professional and drug development scientist specializing in early clinical development services at Vince and Associates Clinical Research. She earned a Ph.D. in Laboratory Medicine and Bioanalytical Chemistry from the Cleveland Clinic Foundation/Cleveland State University Consortium. She has significant drug development expertise in the biotechnology industry as well as operational expertise in early clinical development contract research organizational leadership. Dr. Rusch provided clinical pharmacology and metabolism expertise on many pre-IND drug development teams, with prior preclinical and early clinical responsibilities for Merck’s Zolinza™, a first-in-class histone deacetylase inhibitor (HDAC) currently approved for the treatment of cutaneous T-cell lymphoma and under study for additional indications.

« Return